These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests. Horst WD; Pool WR; Spiegel HE Eur J Pharmacol; 1973 Mar; 21(3):337-42. PubMed ID: 4736076 [No Abstract] [Full Text] [Related]
4. Parkinsonism: animal analogues of the human disorder. Duvoisin RC Res Publ Assoc Res Nerv Ment Dis; 1976; 55():293-303. PubMed ID: 826997 [No Abstract] [Full Text] [Related]
5. Some benzhydryl derivatives as central dopamine receptor stimulating agents. van Beek MC; Timmerman H J Pharm Pharmacol; 1974 Jan; 26(1):57-8. PubMed ID: 4150936 [No Abstract] [Full Text] [Related]
6. The effect of anti-Parkinson drugs on catalepsy induced by -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine. Cashin CH; Sutton S Br J Pharmacol; 1973 Mar; 47(3):658P-659P. PubMed ID: 4738385 [No Abstract] [Full Text] [Related]
7. Modification of the tremorigenic activity of physostigmine. Ambrani LM; Van Woert MH Br J Pharmacol; 1972 Oct; 46(2):344-7. PubMed ID: 4651776 [TBL] [Abstract][Full Text] [Related]
8. Dopamine release and direct dopamine receptor activation in the central nervous system by D-145, an amantadine derivative. Svensson TH Eur J Pharmacol; 1973 Sep; 23(3):232-8. PubMed ID: 4746740 [No Abstract] [Full Text] [Related]
9. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra. Biggs CS; Fisher A; Starr MS Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134 [TBL] [Abstract][Full Text] [Related]
11. L-DOPA-chlorpromazine antagonism on running activity in mice. Derkach P; Larochelle L; Bieger D; Hornykiewicz O Can J Physiol Pharmacol; 1974 Feb; 52(1):114-8. PubMed ID: 4825682 [No Abstract] [Full Text] [Related]
12. A preliminary report on the action of imipramine and antiparkinsonian agents on the open field behaviour of rats. Kulkarni SK; Dandiya PC Jpn J Pharmacol; 1974 Oct; 24(5):809-10. PubMed ID: 4477250 [No Abstract] [Full Text] [Related]
13. Synthesis and antireserpine activity of peptides of L-dopa. Felix AM; Winter DP; Wang SS; Kulesha ID; Pool WR; Hane DL; Sheppard H J Med Chem; 1974 Apr; 17(4):422-6. PubMed ID: 4857423 [No Abstract] [Full Text] [Related]
14. Evidence for the presence of dopaminergic nerves and receptors in the intestine of a mollusc, Tapes watlingi. Dougan DF; Mclean JR Comp Gen Pharmacol; 1970 Mar; 1(1):33-46. PubMed ID: 4125747 [No Abstract] [Full Text] [Related]
15. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum. Biggs CS; Starr MS Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170 [TBL] [Abstract][Full Text] [Related]
16. Central actions of dopa and dopamine. Sourkes TL Rev Can Biol; 1972; 31():Suppl:153-68. PubMed ID: 4403289 [No Abstract] [Full Text] [Related]
17. Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain. Fisher A; Starr MS Brain Res; 2000 Jun; 868(2):268-74. PubMed ID: 10854579 [TBL] [Abstract][Full Text] [Related]
18. The role of the adrenergic system in the action of L-DOPA on brain serotonin. Algeri S; Cerletti C Adv Biochem Psychopharmacol; 1974; 10():257-9. PubMed ID: 4846542 [No Abstract] [Full Text] [Related]
19. The effect of antiparkinson drugs on the liguomandibular reflex in cats. Barnett A; Fiore JW Eur J Pharmacol; 1973 Feb; 21(2):178-82. PubMed ID: 4696100 [No Abstract] [Full Text] [Related]
20. Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease. Löschmann PA; Eblen F; Wüllner U; Wachtel H; Kockgether T Eur J Pharmacol; 1995 Sep; 284(1-2):129-34. PubMed ID: 8549615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]